Overview

A Study Comparing Blood Flow and Clinical and Safety Effects of the Addition of Natrecor (Nesiritide), Placebo or Intravenous Nitroglycerin to Standard Care for the Treatment of Worsening Congestive Heart Failure.

Status:
Completed

Trial end date:
2000-08-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to compare the hemodynamic (blood flow) and clinical effects of the study drug, Natrecor (nesiritide, a recombinant form of the natural human peptide normally secreted by the heart in response to heart failure) to those of intravenous nitroglycerin or placebo, when added to the standard care therapy that is usually administered in the treatment of patients with worsening congestive heart failure.

Phase:

Phase 3

Details

Lead Sponsor:

Scios, Inc.

Treatments:

Natriuretic Peptide, Brain
Nitroglycerin